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Background: Thrombocytopenia is a significant problem in patients with relapsed or refractory multiple myeloma,
precipitating a need for supportive platelet transfusions and necessitating decreases in delivered doses of chemotherapy.
Eltrombopag is a non-peptide, small molecule thrombopoietin (TPO) receptor agonist that promotes megakaryopoiesis
similar to endogenous human TPO and may be an effective agent for thrombocytopenia in this patient population.
Methods:We examined the effects of eltrombopag on megakaryocyte colony-forming capacity in CD34+ cells in patients
with multiple myeloma and investigated its impact on proliferation, viability, and apoptosis in primary CD138+ human
myeloma cells and myeloma cell lines.
Results: Eltrombopag at doses of 0.1 to 100 μM did not enhance proliferation of primary human CD138+
multiple myeloma cells from patients with relapsed disease or myeloma cell lines when used alone or in
combination with erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) and did not alter cell
viability nor apoptosis of human myeloma cells exposed to bortezomib and lenalidomide. Eltrombopag stimulated
megakaryopoiesis in human CD34+ cells from normal individuals and from patients with relapsed multiple myeloma
via activation of Akt signaling pathways.
Conclusions: These results provide proof-of-principle supporting the design of future clinical studies examining
eltrombopag for the treatment of thrombocytopenia in patients with advanced multiple myeloma.
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Clinically significant thrombocytopenia is a common prob-
lem in patients with relapsed or refractory multiple mye-
loma, resulting in increased bleeding complications,
administration of supportive platelet transfusions, and ne-
cessitating reductions in delivered doses of chemotherapy.
The etiology of thrombocytopenia in this patient popula-
tion is multifactorial, often involving cytotoxic effects of
chemotherapeutic agents on megakaryocytes, suppression* Correspondence: jyjeong@kosin.ac.kr
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unless otherwise stated.of normal hematopoiesis by malignant cells, and cumulative
disease- and therapy-related abnormalities affecting the
bone marrow stromal microenvironment. Agents such as
bortezomib, a potent reversible proteasome inhibitor [1],
have been shown to be highly active in patients with re-
lapsed or refractory multiple myeloma [2,3]. However, the
most common grade 3 adverse event noted during clinical
trials with bortezomib was cyclic thrombocytopenia, occur-
ring in 24% and 28% of trial participants [4,5], potentially
limiting intensity of dosing regimens.
Thrombopoietin (TPO) is synthesized in the liver and is
the primary regulator of megakaryocyte development and
platelet formation and is the ligand for the c-mpl cytokine
receptor [6,7], which is present on the surfaces of cells ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Human multiple myeloma cells do not express MPL. cDNA
(10 ng/sample) prepared from primary CD138+ multiple myeloma cells
(four representative patient samples) and from the KMS-11 and OCI-My5
human myeloma cell lines was used as a template to amplify a specific
144 bp fragment of the human MPL gene and a 797 bp fragment
of the GAPDH gene by RT-PCR. cDNA prepared from normal CD34+ cells
cultured in the presence of 100 ng/ml rhTPO for 4 days or K562
cells were used as positive and negative controls, respectively.
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hematopoietic progenitors [8,9]. TPO-mediated c-mpl
activation promotes not only the proliferation and dif-
ferentiation of megakaryocytic progenitors but also en-
hances the viability of pluripotent stem cells and early
progenitor cells of all hematopoietic lineages [10,11].
Recombinant human TPO (rhTPO) was previously shown
to attenuate carboplatin-induced severe thrombocytopenia
and reduce the need for supportive platelet transfusions in
patients with gynecologic cancer [12]. However, clinical
development of rhTPO for the treatment of chemotherapy-
associated thrombocytopenia was discontinued due to the
formation of neutralizing anti-TPO antibodies and subse-
quent development of thrombocytopenia associated with
the use of pegylated recombinant human megakaryocyte
growth and development factor (PEG-rHuMGDF) [12].
Eltrombopag is an orally bioavailable, non-peptide, small
molecule c-mpl agonist that has been shown in both
in vitro and in vivo studies to promote megakaryocyte pro-
liferation and differentiation in a manner similar to that
seen with endogenous human TPO [13]. Eltrombopag re-
ceived accelerated FDA approval in the United States for
the treatment of patients with chronic idiopathic throm-
bocytopenic purpura (ITP) in 2008 and full approval in
2011. Eltrombopag has been shown to effectively increase
platelet counts and reduce thrombocytopenia-associated
complications in patients with ITP and hepatitis C [14-16].
In addition, preclinical studies evaluating the effects of
eltrombopag on bone marrow cells from patients with mye-
lodysplastic syndrome (MDS) or acute myeloid leukemia
(AML) found that it promoted normal megakaryopoiesis
without inducing clonal expansion of malignant cells [17].
In this study, we addressed whether eltrombopag may
promote megakaryopoiesis in bone marrow progenitors
of patients with relapsed multiple myeloma without
inducing proliferation of multiple myeloma cells or
inhibiting immunomodulatory drug cytotoxicity. We
found that eltrombopag did not stimulate the proliferation
nor enhance the cell viability of human myeloma cell
lines or primary CD138+ myeloma cells and did not
alter drug-induced apoptosis of myeloma cells in
patients with relapsed disease. Furthermore, we show
that eltrombopag promotes megakaryopoiesis in CD34+
cells isolated from myeloma patients and healthy
controls via activation of Akt signaling pathways,
providing preclinical proof-of-principle to support the
design of future clinical trials examining eltrombopag
for the treatment of thrombocytopenia in patients with
relapsed multiple myeloma.
Results
Multiple myeloma cells do not express MPL
We examined whether c-mpl was expressed on human
myeloma cell lines or primary CD138+ myeloma cells frompatients with relapsed disease. Primary myeloma cells from
each patient were found to be ≥95% CD138+/CD19−, as
assessed by staining with CD138-PE and CD19-APC anti-
bodies as previously described [18]. cDNA was prepared
from the KMS-11 and OCI-My5 cell lines and from pri-
mary CD138+ myeloma cells from four subjects, and a spe-
cific 144 bp fragment of the human MPL gene and a
797 bp fragment of the GAPDH gene were amplified by
PCR. cDNA prepared from normal CD34+ cells cultured in
the presence of 100 ng/ml rhTPO for 4 days or K562 cells
[19] were used as positive and negative controls, respect-
ively. As shown in Figure 1, MPL gene expression was not
detected in multiple myeloma cell lines or in primary
CD138+ myeloma cells, suggesting that eltrombopag would
be unlikely to stimulate the growth of human myeloma
cells via activation of c-mpl-dependent signaling pathways.
Eltrombopag does not enhance the proliferation of
human multiple myeloma cell lines
We next investigated whether eltrombopag affects the
proliferative capacity of human myeloma cells via c-mpl-
independent pathways, either alone or in combination
with other hematopoietic growth factors such as granulo-
cyte colony-stimulating factor (G-CSF) and erythropoietin
(EPO), which are often used as supportive therapy to treat
cytopenias associated with anti-myeloma therapy. Prolifer-
ation of KMS-11 and OCI-My5 cell lines was analyzed in
the presence of varying concentrations of eltrombopag
(0–100 μM) or 100 ng/ml rhTPO in the presence or
absence of 10 ng/ml G-CSF and 3 U/ml EPO over a period
of 6 days. We found that eltrombopag or rhTPO did not
enhance the proliferation of both KMS-11 and OCI-My5
at all concentrations tested either alone or in combination
with G-CSF and EPO (Figure 2A,B). Similar results were
observed with incubating cells for 3 or 9 days (data not
shown). We also noted that the 100 μM concentration of
Figure 2 Eltrombopag does not enhance proliferation of human
myeloma cell lines. (A) KMS-11 or (B) OCI-My5 cells were incubated with
varying concentrations of eltrombopag in the presence or absence
of G-CSF (10 ng/ml) and EPO (3 U/ml) for 6 days and cell viability
determined by measuring fluorescence signals at 535Ex/595Em using the
CellTiter Blue Assay. Data are presented as mean ± S.D. of triplicate
experiments. *p < 0.02. ELT = eltrombopag; TPO = thrombopoietin;
CTRL = control.
Figure 3 Eltrombopag does not inhibit bortezomib or lenalidomide-
induced apoptosis of human myeloma cell lines. (A) KMS-11 or
(B) OCI-My5 cells were incubated with varying concentrations of
eltrombopag in the presence or absence of 1 μM lenalidomide
and 10 nM bortezomib for 24 h and apoptosis determined by
measuring activation of caspase-3 and −7 activity. Data are
presented as mean ± S.D. of triplicate experiments. *p < 0.02.
ELT = Eltrombopag; TPO = thrombopoietin; CTRL = control;
Len = lenalidomide; Btz = bortezomib.
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viability of KMS-11 and OCI-My5 cells, which is in
agreement with other studies showing cell cytostatic/
cytotoxic effects associated with this high concentration of
eltrombopag [20].
Eltrombopag does not alter chemotherapy-induced
apoptosis of multiple myeloma cell lines
Chemotherapy regimens incorporating the use of borte-
zomib [3,5] or lenalidomide [21] are increasingly becom-
ing standard of care in the treatment of patients with
relapsed multiple myeloma. Because of this, we wanted
to ensure that eltrombopag did not inhibit drug-induced
apoptosis of human myeloma cell lines. KMS-11 and
OCI-My5 cells were grown in the presence of varying
concentrations of eltrombopag (0–100 μM) or 100 ng/ml
rhTPO in the presence or absence of 1 μM lenalidomide
and 10 nM bortezomib and apoptosis determined via
measurement of caspase-3 and −7 activation at 24 h. The
combination of lenalidomide and bortezomib induced5.3-fold and 1.7-fold increases in apoptosis in KMS-11
and OCI-My5 cells, respectively, compared to control,
and the degree of apoptotic activity was not altered by
the presence of eltrombopag or rhTPO at all concen-
trations tested (Figure 3A,B).
Eltrombopag does not enhance proliferation or alter
chemotherapy-induced apoptosis of primary human
CD138+ myeloma cells
We next evaluated eltrombopag’s effects on primary
human myeloma cells. Equal numbers (5,000/well) of
CD138+/CD19− myeloma cells isolated from bone marrow
of patients with relapsed multiple myeloma (n = 7) were
cultured in the presence of varying concentrations of
eltrombopag (0–100 μM) or 100 ng/ml rhTPO in the pres-
ence or absence of 10 ng/ml G-CSF and 3 U/ml EPO for
24 h and then exposed to 1 μM lenalidomide and 10 nM
bortezomib for an additional 24 and 48 h to measure apop-
tosis and cell proliferation, respectively. Eltrombopag at
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rhTPO did not alter cell viability in the presence or absence
of G-CSF and EPO (Figure 4A). Cell proliferation studies
revealed that the addition of 1 μM lenalidomide and 10 nM
bortezomib resulted in 60% decreased cell viability of
CD138+ myeloma cells, and this decreased viability was
not inhibited by eltrombopag or rhTPO (Figure 4A).
Apoptosis of CD138+ myeloma cells was not altered by
either eltrombopag at concentrations up to 10 μM or
100 ng/ml rhTPO in the presence or absence of G-CSF
and EPO (Figure 4B). Cells grown in the presence of lenal-
domide and bortezomib exhibited 2.3-fold greater apop-
tosis, and this was again not altered by either eltrombopag
or rhTPO (Figure 4B). We found that 100 μM eltrombo-
pag enhanced apoptosis, resulting in markedly decreased
CD138+ cell viability (Figure 4A,B).Figure 4 Eltrombopag does not enhance proliferation or alter
apoptosis of primary human CD138+ myeloma cells. Human primary
CD138+ multiple myeloma cells from patients with relapsed multiple
myeloma (n = 7) were incubated with varying concentrations of
eltrombopag in the presence or absence of G-CSF (10 ng/ml) and
EPO (3 U/ml) and in the presence or absence of lenalidomide
(1 μM) and bortezomib (10 nM). (A) Cell viability was determined
by measuring fluorescence signals at 535Ex/595Em using the CellTiter Blue
Assay (*p < 0.01). (B) Apoptosis was assessed by measuring activation
of caspase-3 and −7 (*p < 0.05). Data are presented as mean ± S.E. of
combined experiments on seven individual patient samples, each
performed in triplicate. ELT = Eltrombopag; TPO = thrombopoietin;
CTRL = control; Len = lenalidomide; Btz = bortezomib.Eltrombopag stimulates the ex vivo expansion of
hematopoietic progenitors
We determined whether eltrombopag, in combination with
other growth factors and early-acting cytokines, would sup-
port the expansion of human hematopoietic progenitors to
an equivalent degree as that seen with rhTPO. Bone
marrow-derived CD34+ cells from normal healthy controls
(n = 8) were cultured in StemSpan medium supplemented
with rhSCF (50 ng/ml), rhIL-3 (10 ng/ml), and rhIL-6
(10 ng/ml) in the presence or absence of 10 μM eltrombo-
pag or 100 ng/ml rhTPO for 11 days, and hematopoietic
progenitor assays were performed as described. CD34+
cells cultured in the presence of 10 μM eltrombopag
were noted to have significant expansion of all
hematopoietic colonies, including increases of 2.6-fold
in CFU-E (p < 0.01), 2.4-fold in BFU-E (p < 0.01), 2.0-fold in
CFU-GM (p < 0.01), and 2.7-fold in CFU-GEMM (p < 0.01)
colonies compared to control (Figure 5A–D). There did
not appear to be a statistically significant difference in
hematopoietic colony expansion between eltrombopag
and rhTPO except for CFU-GEMM, where eltrombo-
pag appeared superior to rhTPO (2.7- versus 1.9-fold;
p < 0.01, t-test). To examine the effect of eltrombopag
on megakaryocyte colony formation (CFU-MK), CD34+
cells cultured as above were similarly measured using
standard MegaCult assays containing 50 ng/ml rhTPO.
CD34+ cells cultured in the presence of 10 μM eltrom-
bopag exhibited a 3.8-fold increase in total MK colonies
compared to control cells (p < 0.01, t-test) and proved
equivalent to 100 ng/ml rhTPO (Figure 5E).
Eltrombopag stimulates megakaryopoiesis in CD34+ cells
isolated from patients with relapsed multiple myeloma
and from normal controls
We next investigated whether eltrombopag is capable of
stimulating megakaryopoiesis in purified CD34+ cells iso-
lated from patients with relapsed multiple myeloma (n = 5).
In Mk progenitor assays, CD34+ cells cultured in the pres-
ence of varying concentrations of eltrombopag (1–10 μM)
exhibited a significant increase in Mk colonies at all doses
tested compared to control cells (p < 0.02, t-test) and
proved equivalent to 50 ng/ml rhTPO (Figure 6A,B).
Similar results were obtained with CD34+ cells iso-
lated from normal controls (n = 4, Figure 6C,D). In li-
quid culture, the percentage of immature and mature
megakaryocytes was assessed by fluorescence-activated cell
sorting (FACS) analysis for CD41a and CD42b expression
on cells cultured for 11 days [22]. Eltrombopag and rhTPO
equivalently produced an immature population of mega-
karyocytes, with 53% being CD41a+/CD42b − and 47% be-
ing CD41a+/CD42b + in average among CD41a + cells
incubated with eltrombopag and 47.5% being CD41a+/
CD42b − and 52.5% being CD41a+/CD42b +when incu-
bated with rhTPO (Figure 6E). In summary, our data
Figure 5 Eltrombopag stimulates the expansion of hematopoietic progenitor cells from normal controls. CD34+ cells cultured in the presence or
absence of 10 μM eltrombopag or 100 ng/ml rhTPO for 11 days were assessed for pluripotency by hematopoietic progenitor assays performed in
semi-solid methylcellulose or MegaCult media. (A) CFU-E, (B) BFU-E, (C) CFU-GM, and (D) CFU-GEMM were enumerated at the end of 14 days
and (E) CFU-Mk at the end of 12 days. Data are presented as mean ± S.E. relative to control from eight individual donors with experiments performed in
triplicate. CTRL = control; ELT = Eltrombopag; TPO= thrombopoietin. *p< 0.02, **p< 0.01.
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poiesis in hematopoietic progenitors from patients with
relapsed multiple myeloma.
Eltrombopag activates Akt in both human platelets and
CD34+ cells
Whereas both eltrombopag and rhTPO appear to activate
STAT proteins, it has been previously reported that in con-
trast to rhTPO, eltrombopag-mediated signaling in human
platelets did not involve Akt phosphorylation [23]. To de-
termine eltrombopag’s effects on Akt signaling during
megakaryopoiesis, we examined whether eltrombopag in-
duces Akt phosphorylation in mature platelets and an earl-
ier stage of megakaryocyte development. Contrary to
previous reports, we found that eltrombopag induced Akt
phosphorylation in human platelets, albeit to a lesser degree
compared to rhTPO (Figure 7A). Next, peripheral blood-
mobilized CD34+ cells isolated from two patients withrelapsed multiple myeloma were cultured as described for
8 days and then cytokine-starved and stimulated with either
eltrombopag or rhTPO. In this group of immature mega-
karyocyte progenitors, we found that both eltrombopag and
rhTPO induced Akt signaling, with eltrombopag exhibiting
less intense and delayed Akt phosphorylation compared to
rhTPO (Figure 7B). Similar degrees of Akt phosphorylation
in response to eltrombopag and rhTPO were also noted in
peripheral blood-mobilized CD34+ cells from normal,
healthy individuals (data not shown).
Discussion
In this study, we examined the effect of the novel non-
peptide thrombopoietin receptor agonist eltrombopag on
human multiple myeloma cell lines and on bone marrow-
derived CD138+ myeloma cells and hematopoietic
progenitors in patients with relapsed multiple myeloma.
Eltrombopag received accelerated FDA approval for the
Figure 6 Eltrombopag stimulates megakaryopoiesis in CD34+ cells isolated from patients with relapsed multiple myeloma. CD34+ cells
isolated from patients with relapsed multiple myeloma (n = 5, A and B) or CD34+ cells from normal controls (n = 4, C and D) were evaluated
in CFU-Mk progenitor assays performed in semi-solid MegaCult media in the presence or absence of 0–10 μM eltrombopag or 50 ng/ml
rhTPO. CFU-Mk colonies were enumerated after incubation for 11 days. Total CFU-Mk numbers are presented in (A) and (C), and differential
colony numbers by their size are presented in (B) and (D). Data are presented as the mean Mk colony number relative to that with 50 ng/ml
TPO (mean ± S.E., n = 5 individual patients or n = 4 normal controls with experiments each performed in triplicate). *p < 0.02 for all doses
tested. ns = not significant. (E) CD34+ cells from normal controls (n = 4 for eltrombopag and n = 2 for rhTPO) were cultured in a serum-free
StemSpan liquid medium containing rhSCF (50 ng/ml), rhIL-3 (10 ng/ml), and rhIL-6 (10 ng/ml) in the presence of 10 μM eltrombopag or
100 ng/ml rhTPO for 11 days, and the surface expression of CD41a and CD42b was analyzed by flow cytometry. Each dot plot represents
individual donor.
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Figure 7 Eltrombopag induces Akt in human platelets and immature megakaryocytes. (A) Platelets from a healthy donor or (B) multiple
myeloma-derived peripheral blood mobilized-CD34+ cells (MM#1 and MM#2) cultured for 8 days were stimulated with 100 ng/ml rhTPO or
10 μM eltrombopag for the indicated times, and immunoblotting was performed to detect the activation of STAT5 and Akt signaling pathways. Note that
p-Akt bands appeared below non-specific bands in human platelets (A) and above non-specific bands in immature megakaryocytes (B). Migration of
molecular weight markers is indicated to the right of each blot.
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approval in 2011. A preclinical study reveals it may sup-
port megakaryopoiesis in patients with MDS/AML [17]. A
recent article reviewed the efficacy and safety of thrombo-
poietin receptor agonists including eltrombopag for the
past 5 years since the FDA approval, summarizing that
eltrombopag effectively increases platelet counts with few
adverse effects [24]. The effects of eltrombopag on patients
with multiple myeloma or other lymphoid malignancies
have not been previously reported. Thrombocytopenia
remains an important clinical consideration in multiple
myeloma, especially in those patients with relapsed or re-
fractory disease [4,5]. Although multiple myeloma remains
an incurable malignancy, the introduction of novel thera-
peutic agents has significantly improved clinical outcomes
in a large number of patients [25,26]. As clinically sig-
nificant thrombocytopenia may predispose to bleeding
and may necessitate the need for dose reductions in
chemotherapy, patients would benefit from an agent
that will stimulate platelet production and thus reduce
the need for supportive platelet transfusions and minimizechemotherapy dose modifications. Our study describes for
the first time the effects of eltrombopag in multiple mye-
loma. We found no evidence to suggest that eltrombopag
promotes proliferation of human multiple myeloma cell
lines or primary CD138+ myeloma cells, and it does not ap-
pear to inhibit the cytotoxic effects of bortezomib or lenali-
domide. Furthermore, we show that eltrombopag is capable
of supporting megakaryopoiesis in hematopoietic progeni-
tors from patients with relapsed multiple myeloma via
pathways that involve Akt activation. These results provide
compelling preclinical evidence that eltrombopag may be a
useful agent for the treatment of thrombocytopenia in
some patients with relapsed or refractory multiple myeloma
and warrants further investigation in controlled clinical
trials.
We used several independent assays to determine
whether eltrombopag had the capacity to promote pro-
liferation of multiple myeloma cells. As MPL gene ex-
pression pattern may vary according to the malignant
cell of origin, being found in MDS/AML but not in
acute lymphoblastic leukemia (ALL) or non-Hodgkin’s
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whether MPL was expressed in human primary myeloma
cells and cell lines. We did not detect MPL expression in
primary CD138+ myeloma cells and myeloma cell lines
by PCR analysis, making it unlikely for eltrombopag to
promote in vitro or ex vivo proliferation of multiple
myeloma cells via c-mpl-dependent pathways. More im-
portantly, we found that eltrombopag did not enhance
the proliferative capacity of primary human CD138+ mye-
loma cells or myeloma cell lines at all doses tested.
Eltrombopag has been shown to reduce proliferation of
non-megakaryocytic leukemia and lymphoma cell lines
[20]. However, we could not detect an anti-proliferative
effect of eltrombopag on the myeloma cell lines we ex-
amined. Although the 100 μM dose of eltrombopag
markedly decreased myeloma cell viability, this likely
reflects a general cell cytotoxic effect rather than a specific
anti-proliferative effect, as this high dose was also noted to
suppress the development of normal hematopoietic pro-
genitor colonies.
The cumulative effect of chemotherapy in patients with
relapsed or refractory multiple myeloma may result in pro-
gressive bone marrow suppression and complications due
to anemia, neutropenia, and thrombocytopenia. The appro-
priate use of erythropoiesis-stimulating agents (ESAs) for
the treatment of chemotherapy-induced anemia is currently
being reevaluated. Although the use of ESAs and G-CSF
may have a beneficial effect in patients with MDS [28,29],
their benefit in multiple myeloma patients remains in ques-
tion [30,31]. Nevertheless, given that growth factors may be
prescribed for some patients with multiple myeloma, we
wanted to determine whether eltrombopag may synergistic-
ally interact with EPO and G-CSF to promote proliferation
of human myeloma cells. Our results demonstrate that
eltrombopag, in combination with EPO and G-CSF, did not
enhance the proliferation of primary human CD138+ mye-
loma cells or myeloma cell lines. Taken together, these pre-
clinical results indicate that eltrombopag at all doses
studied does not enhance the proliferative capacity of pri-
mary human CD138+ myeloma cells from patients with re-
lapsed disease or myeloma cells lines. Eltrombopag was
also found not to abrogate the apoptotic activity or cytotox-
icity of either bortezomib or lenalidomide, an important
consideration given the widespread use of these agents in
patients with relapsed multiple myeloma and increased ad-
ministration as front-line therapy. However, due to the lim-
ited number of patient samples examined in our study, we
cannot say that eltrombopag may not adversely affect the
proliferation of multiple myeloma in particular subgroups
of patients and does not take into account the potential for
deleterious interactions with the bone marrow microenvir-
onment. Therefore, our data will need to be further ana-
lyzed and confirmed in larger numbers of patients to
determine whether eltrombopag will prove to be a safe andefficacious treatment for thrombocytopenia in subgroups of
multiple myeloma patients. Other safety concerns such as
thrombosis risk and fibrosis risk in multiple myeloma pa-
tients should be considered as well. Based on clinical trials
of eltrombopag in other diseases, these risks appeared to be
minimal to negligible unless longer than 2–3 years of treat-
ment is required [24]. Therefore, it is highly unlikely that
eltrombopag increases the risk for thrombosis and/or fibro-
sis since eltrombopag would only be used on an intermit-
tent basis to support platelet counts in multiple myeloma
patients before or after chemotherapy. Nevertheless,
potential adverse effects should be fully evaluated in fu-
ture clinical trials.
We show for the first time that eltrombopag is capable
of stimulating megakaryopoiesis in CD34+ cells isolated
from patients with relapsed multiple myeloma and did
so to a degree equivalent to that of rhTPO. The use of
rhTPO or megakaryocyte-derived growth factor (MDGF)
for the treatment of thrombocytopenia in multiple mye-
loma patients has not been previously evaluated. rhTPO,
when used in combination with other cytokines, has
been shown to support the ex vivo expansion of mega-
karyocyte progenitors from normal bone marrow and
peripheral blood and from patients with hematological
malignancies [32]. In patients undergoing autologous
stem cell transplantation (ASCT) following high-dose
chemotherapy, combined administration of G-CSF and
rhTPO enhanced the mobilization of CD34+ hematopoietic
progenitors, resulting in a statistically significant reduction
in time to neutrophil recovery as well as reduction in the
number of platelet and red blood cell transfusions [33].
However, the clinical utility of rhTPO was limited by drug-
associated immunogenicity in humans [34], necessitating
the discontinuation of clinical development of these agents.
Our study shows that eltrombopag supports the expansion
of human hematopoietic progenitors to an equivalent de-
gree as that seen with rhTPO. Both eltrombopag and
rhTPO also favored the development of more immature
megakaryocytic progenitors, as evidenced by greater cell
surface expression of CD41a (glycoprotein IIb/IIIa) and
relative lack of expression of CD42b (glycoprotein Ib),
which is a similar pattern to that noted previously with
rhTPO [22]. Contrary to a previous report [23], we found
that eltrombopag induces activation of Akt in both human
platelets and immature megakaryocytes but does so to a
lesser degree and with different kinetics compared to
rhTPO. Our finding may reflect greater sensitivity of pres-
ently available Akt antibodies or biological differences in
patient samples examined. The biological or clinical signifi-
cance of eltrombopag-mediated Akt activation in patients
with lymphoid malignancies remains to be determined.
Overall, our data suggest that eltrombopag may prove to be
a clinically useful alternative to rhTPO for stimulating
megakaryopoiesis in relapsed multiple myeloma patients.
Jeong et al. Journal of Hematology & Oncology  (2015) 8:37 Page 9 of 11Conclusions
Our preclinical study provides proof-of-principle demon-
strating that eltrombopag is capable of stimulating mega-
karyopoiesis in CD34+ cells from patients with relapsed
multiple myeloma and does not promote proliferation of
human primary multiple myeloma cells or myeloma cell
lines. Furthermore, no synergistic effect on myeloma cell
growth was noted with the combination of eltrombopag,
EPO, and G-CSF, and eltrombopag did not appear to re-
verse the cytotoxic or apoptotic effects of lenalidomide or
bortezomib. Insights garnered from this study will help
form the basis for larger preclinical studies examining the
effects of eltrombopag on hematopoiesis in multiple mye-
loma and provides a rationale to support the design of fu-
ture clinical trials evaluating the use of eltrombopag for the
treatment of thrombocytopenia in patients with relapsed
multiple myeloma as well as other lymphoid malignancies.
Methods
Reagents
Eltrombopag was provided by GlaxoSmithKline. Eltrombo-
pag was dissolved in sterile distilled deionized water at a
10 mM stock concentration and stored light-protected at
room temperature and used within 2 weeks of preparation.
Patient samples
Bone marrow (n = 4) and G-CSF-mobilized peripheral
blood hematopoietic progenitor (n = 4) samples were ob-
tained from patients with relapsed multiple myeloma
within the framework of routine standard of care under
the auspice of Dana-Farber Cancer Institute protocol
(DFCI) 01–206 after obtaining written informed consent
in accordance with the Declaration of Helsinki. Purified
human CD138+ multiple myeloma cells (n = 3) or bone
marrow mononuclear cells [BM-MNC (n = 2)] from
bone marrow from patients with relapsed multiple
myeloma were also obtained from commercial sources
(AllCells, Emeryville, CA and Proteogenix, Oberhausberger,
France, respectively). Cryopreserved bone marrow-derived
(n = 8) or peripheral blood-mobilized (n = 2) human
CD34+ cells from healthy controls were purchased
from Lonza (Basel, Switzerland) and AllCells, respect-
ively. Normal human platelets were obtained from the
Transfusion Medicine Service at Brigham and Women’s
Hospital (Boston, MA).
Isolation of human CD138+ multiple myeloma and CD34+
cells
Bone marrow aspirates and mobilized peripheral blood
progenitors were processed by density centrifugation
using Ficoll-Hypaque to obtain BM-MNC and PB-MNC,
respectively. CD138+ myeloma cells and CD34+ cells
were purified using anti-CD138 and anti-CD34 immuno-
magnetic bead selection, respectively, by AutoMACScolumn purification (Miltenyi Biotec, Auburn, CA) ac-
cording to the manufacturer’s instructions.
Culturing primary multiple myeloma cells and cell lines
Human multiple myeloma cell lines KMS-11 and OCI-
My5 were kindly provided by Dr. Constantine Mitsiades
of DFCI and were maintained in RPMI-1640 (Invitrogen,
Carlsbad, CA) containing 10% fetal bovine serum (FBS;
Invitrogen) and 1 × antibiotic-antimycotic (AA; Invitro-
gen). Primary human CD138+ multiple myeloma cells
were cultured for up to 72 h in RPMI-1640 with 20%
FBS, 1 × AA, and the following combination of cyto-
kines each at 10 ng/ml: interleukin six (rhIL-6), vascular
endothelial growth factor (rhVEGF), insulin-like growth
factor-1 (rhIGF-1), hepatocyte growth factor (rhHGF), and
rhIL-13 (all from Peprotech, Rocky Hill, NJ). The K562
cell line was cultured in RPMI-1640 containing 10% FBS
and 1 × AA. All cell cultures were maintained at 37°C in a
humidified atmosphere of 95% air and 5% CO2.
Hematopoietic progenitor cell assays
CD34+ cells were cultured in StemSpan serum-free
expansion medium (StemCell Technologies) containing
recombinant human stem cell factor (rhSCF, 50 ng/ml),
interleukin-3 (rhIL-3, 10 ng/ml), rhIL-6 (10 ng/ml, all
from Peprotech), and low-density lipoprotein (40 μg/ml,
Sigma-Aldrich), in the presence or absence of eltrombopag
(10 μM) or rhTPO (100 ng/ml, Peprotech) and 1 × AA
for 11 days. Cell density was maintained in a range of
1 × 105–2 × 106 cells/ml by replenishing with fresh
medium on days 4 and 7. Cultured cells were plated in
triplicate in 35-mm dishes (5,000 total cells per dish) in
a semisolid methylcellulose medium consisting of 80%
methocult H4230 media (StemCell Technologies) and 20%
IMDM (Invitrogen), supplemented with 50 ng/ml rhSCF,
10 ng/ml rhIL-3, 10 ng/ml granulocyte-macrophage
colony-stimulating factor (GM-CSF; PeproTech), 1 U/ml
erythropoietin (EPO; R&D Systems, Minneapolis, MN),
and 1 × AA. Colony-forming unit-erythroid (CFU-E),
burst-forming unit-erythroid (BFU-E), CFU-granulocyte/
macrophage (CFU-GM), and CFU-granulocyte/erythrocyte/
monocyte/megakaryocyte (CFU-GEMM) were scored using
an inverted microscope (Nikon, Tokyo, Japan) 14 days
following plating. Megakaryocytic colony (CFU-Mk) forma-
tion was assessed using the Megacult-C CFU-Mk assay kit
(StemCell Technologies) according to the manufacturer’s
instructions. Briefly, CD34+ cells were plated in triplicate in
dual-chamber slides (DCS) (2,500 cells per DCS) in semi-
solid Megacult-C medium supplemented with 10 ng/ml
rhIL-3 (PeproTech), 10 ng/ml rhIL-6 (Peprotech), and
40 μg/ml LDL (Sigma-Aldrich), in the presence or absence
of varying concentrations of eltrombopag (0–10 μM) or
50 ng/ml rhTPO. Megakaryocyte colonies were scored by
immunocytochemical stainings with anti-human GPIIb/IIIa
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avidin-alkaline phosphatase conjugate, and alkaline phos-
phatase substrate. CFU-Mk were defined as clusters of
more than three CD41a + cells [35]. Colonies containing
both CD41a + and CD41a − cells were scored as mixed col-
onies originating from the most immature progenitors cap-
able of differentiating into erythroid and Mk cells.
Flow cytometry
Cells were washed in 4°C in phosphate-buffered saline
(PBS) containing 1% FBS and stained with the following
human monoclonal antibodies: fluorescein isothiocyanate
(FITC)-conjugated CD34 (BD Biosciences, San Diego,
CA), phycoerythrin (PE)-conjugated CD138 (Miltenyi
Biotec), allophycocyanin (APC)-conjugated CD19 (Miltenyi
Biotec), APC-CD41a, and PE-CD42b. Non-viable cells were
excluded by counter staining with 7-AAD (BD Biosciences).
Isotype-matched FITC- or PE-conjugated antibodies were
used as controls. Cells were analyzed on a FACScaliber cyt-
ometer (BD Biosciences) using Cellquest Pro Software (BD
Biosciences) or Flowing Software (flowingsoftware.com).
Reverse transcription polymerase chain reaction
Total RNA was isolated from cells using the RNAqueous-4
PCR kit (Invitrogen) or the RNAqueous-Micro kit (Invitro-
gen), including DNase I treatment, according to the manu-
facturer’s instructions. First-strand cDNA was generated by
using the RETROscript kit (Invitrogen) with a random dec-
amer primer. MPL gene expression was determined by
end-point polymerase chain reaction (PCR) using the sense
primer (5′-atgctagctcccaaggcttcttct) and the antisense pri-
mer (5′-acttgaagtggcagcgagagaact) with a modified touch-
down PCR cycle: 94°C/5 min, 20 cycles of 94°C/30 s–65°C
(−0.5°C per cycle)/30 s–72°C/30 s, 20 cycles of 94°C/30 s–
55°C/30 s–72°C/30 s, 72°C/5 min. The levels of GAPDH in
the same templates were determined by semi-quantitative
PCR using the sense primer (5′-aaggctgagaacgggaagctt)
and the antisense primer (5′-tccaccaccctgttgctgta) as
above.
Multiple myeloma cell proliferation and apoptosis assays
Equal numbers of either primary CD138+ myeloma cells
(5,000 cells/well) or myeloma cell lines (1,000 cells/well)
were plated in 96-well fluorescence/luminescence compat-
ible plates (Corning, Corning, NY) in triplicate in the pres-
ence or absence of varying concentrations of eltrombopag
(0.1–100 μM) or rhTPO (100 ng/ml) as well as in the pres-
ence or absence of G-CSF (10 ng/ml) and EPO (3 U/ml)
for varying periods of time as described. Cell viability was
determined using the CellTiter Blue Assay (Promega,
Madison, WI) measuring fluorescence signals at 535Ex/
595Em according to the manufacturer’s instructions and
confirmed by incorporation of 5-bromo-2-deoxyuridine(BrdU; BrdU in situ detection kit, BD Pharmingen, San
Diego, CA).
To measure apoptosis, subsets of the plated cells cultured
as above at concentrations of 5,000 cells/well for primary
CD138+ myeloma cells and 10,000 cells/well for myeloma
cell lines were treated with or without lenalidomide (1 μM)
and bortezomib (10 nM). Apoptosis was determined 24 h
post treatment with lenalidomide/bortezomib by measuring
caspase-3 and −7 chemiluminescent activities using the
Caspase-Glo 3/7 assay system (Promega) according to the
manufacturer’s instructions. Fluorescence/luminescence
signals were measured using a DTX880 Multimode De-
tector (Beckman Coulter, Brea, CA). All plates contained
control wells with medium alone and additional control
wells with medium plus eltrombopag. All sample data was
processed with corresponding controls.
Signal transduction experiments
Human platelets or CD34+ cells cultured in StemSpan
medium containing 50 ng/ml rhSCF, 10 ng/ml rhIL-3,
10 ng/ml rhIL-6, 100 ng/ml rhTPO, and 1 × AA for
8 days were cytokine-starved in RPMI-1640 medium
containing 0.5% FBS for 3 h. Cells were stimulated with
either 10 μM eltrombopag or 100 ng/ml rhTPO for
specified durations, and whole cell lysates were pre-
pared with 2 × sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) sample buffer contain-
ing Protease Inhibitor Cocktail Set III (CalBiochem/
EMD Chemicals, Gibbstown, NJ, USA) and Phosphat-
ase Inhibitor Cocktail Set III (CalBiochem) and boiled
for 5 min. Immunoblotting was performed using anti-
bodies specific for signal transducers and activators of tran-
scription (STAT)-5, phospho-STAT5, phospho-Akt, and
Akt (all from Cell Signaling Technology, Danvers, MA).
Statistical analysis
Data are presented as mean ± standard error (SE) or
standard deviation (SD). Differences between two groups
of data were analyzed using the Student’s t-test. The
level of significance was set at p value less than 0.05.
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